Technology

Why It Matters

The extended battery life cut healthcare costs and patient risk, making long‑term cardiac pacing a practical, widely adopted therapy.

Key Takeaways

• Lithium‑iodide batteries debuted in 1972 for pacemakers
• Extended device life from 1‑2 years to 10+ years
• Reduced surgical replacements, lowering patient risk and costs
• Paved way for modern implantable cardiac devices and defibrillators
• Inspired subsequent lithium‑based battery research for medical implants

Pulse Analysis

The first implantable pacemakers relied on mercury‑zinc cells that required replacement every one to two years, a frequency that limited widespread clinical adoption. In 1972, Wilson Greatbatch introduced a lithium‑iodide chemistry that could sustain a constant voltage for a decade or more, effectively eliminating the need for frequent battery changes. This breakthrough not only solved a critical reliability problem but also set a new engineering standard for low‑drain, long‑life medical power sources, catalyzing a wave of innovation across cardiac rhythm management. The longer power window enabled smaller enclosures, expanding implants to pediatric and elderly patients.

The longevity of lithium‑iodide batteries translated directly into lower healthcare expenditures. By extending device life to ten years, hospitals reduced the frequency of invasive replacement procedures, cutting operating‑room costs, anesthesia use, and post‑operative complications. Patients benefited from fewer surgeries, improved quality of life, and decreased infection risk. From 2000‑2025, pacemaker sales grew 6 % CAGR, fueled by lithium‑iodide reliability. This cost‑effectiveness spurred insurers and health systems to reimburse advanced pacing technologies more readily, fueling a rapid expansion of the cardiac device market that now exceeds $10 billion globally.

Building on the lithium‑iodide legacy, manufacturers are now exploring lithium‑ion and solid‑state chemistries to push energy density and shrink device footprints further. These next‑generation power sources promise multi‑decade lifespans, wireless recharging, and integration with remote monitoring platforms, opening new revenue streams for medtech firms. The FDA now mandates long‑term biocompatibility data for new chemistries. As the industry balances innovation with patient safety, the original lithium‑iodide breakthrough remains a benchmark for reliability in implantable medical technology.